The earnings call highlighted several positive developments, such as growth in specific product lines, new patents, and certifications. However, these were overshadowed by significant revenue declines, issues with regulatory approvals, and financial challenges. While there are strategic efforts underway to address these issues, the current financial and operational setbacks present substantial challenges.

Company Guidance

During the investor presentation call for Tissue Regenix Group plc, the management team, including Executive Chairman Jay LeCoque, Chief Executive Officer Daniel Lee, and Interim Chief Financial Officer Brandon Largent, provided an overview of the company's financial performance and strategic initiatives. The company reported a 6% decline in group revenues for the first half of 2025 compared to the previous year, with the U.S.-based BioRinse business down 7% and the dCELL business down 4%. Despite these downturns, orders for demineralized bone matrix products increased by 4%, and the dCELL direct business grew by 10%. Gross profit decreased due to lower production yields and increased inventory costs, while adjusted EBITDA also fell year-over-year. The team highlighted significant advancements, such as receiving an EU patent for the dCELL process and MDR certification for the OrthoPure XT product. They also addressed issues related to delays in obtaining Certificates of Foreign Governments from the FDA, impacting the release donor tissue business, which saw a 45% decrease. The management team emphasized their commitment to strengthening the company's commercial approach, reviewing cost structures, and expanding geographically, despite current regulatory headwinds, to ensure sustainable long-term growth.

Growth in dCELL Business

Despite challenges, the dCELL business grew by 10% year-over-year in H1 2025.

EU Patent and MDR Certification

Received an EU patent for the dCELL process and MDR certification, securing IP protection and compliance with new medical device regulations.

Increase in Demineralized Bone Matrix Orders

Orders for demineralized bone matrix products increased by 4% in H1 2025.

Publication of OrthoPure XT Clinical Results

The 5-year clinical results of OrthoPure XT were published in the Journal of Experimental Orthopaedics.

Tissue Regenix (GB:TRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:TRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jun 04, 2026	2025 (Q4)	- / -	-0.005	―	―	―
Sep 30, 2025	2025 (Q2)	- / >-0.01	-0.003	-225.00% (>-0.01)	―	―
Jun 25, 2025	2024 (Q4)	0.00 / >-0.01	-0.009	44.44% (<+0.01)	―	―
Sep 10, 2024	2024 (Q2)	- / >-0.01	-0.01	69.23% (<+0.01)	―	―
Mar 19, 2024	2023 (Q4)	- / >-0.01	-0.014	35.71% (<+0.01)	―	―
Sep 05, 2023	2023 (Q2)	- / >-0.01	-0.015	35.00% (<+0.01)	―	―
Mar 21, 2023	2022 (Q4)	- / -0.01	―	―	―	―
Sep 07, 2022	2022 (Q2)	- / -0.02	-0.02	25.93% (<+0.01)	―	―
Mar 15, 2022	2021 (Q4)	- / -	-0.105	―	―	―
Sep 08, 2021	2021 (Q2)	- / -0.02	-0.161	87.32% (+0.14)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:TRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Sep 30, 2025	21.00p	13.25p	-36.90%
Jun 25, 2025	30.50p	31.00p	+1.64%
Sep 10, 2024	64.00p	62.00p	-3.13%
Mar 19, 2024	68.50p	62.00p	-9.49%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Tissue Regenix Group PLC (GB:TRX) report earnings?

Tissue Regenix Group PLC (GB:TRX) is schdueled to report earning on Jun 04, 2026, TBA (Confirmed).

What is Tissue Regenix Group PLC (GB:TRX) earnings time?

Tissue Regenix Group PLC (GB:TRX) earnings time is at Jun 04, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Tissue Regenix Group PLC stock?

The P/E ratio of Tissue Regenix is N/A.

What is GB:TRX EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing